THE HEART OF THE MATTER

Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The company is focused on the development of minimally-invasive treatments for two of the most vexing challenges in cardiology today; refractory angina and mitral regurgitation. We believe there is tremendous potential in addressing these hard-to-treat conditions.

Neovasc is a publicly-traded company on both the NASDAQ and Toronto stock exchanges.

 

NVCN

NASDAQ

TORONTO (TSX)

Neovasc Q4 Corporate
Strategy Update

Download latest corporate report

download .pdf >

Q4 2022 Financial Report

View/Download Here (.pdf) >